Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment

Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.

SHARE